Shares of Laserscope (LSCP) soared 22 percent to $24.11 as the
earnings outlook for the medical devices company improved dramatically
on news that it will receive much higher reimbursement than it did
previously for one of its procedures. The San Jose, Calif. company
said a reclassification of its photoselective vaporization procedure
for the treatment of enlarged prostate by the centers for Medicare and
Medicaid Sevices means it will now be reimbursed at a rate of $3,750,
twice that of the old rate.
lightshow - 06 Apr 2004 03:01 GMT
> Shares of Laserscope (LSCP) soared 22 percent to $24.11 as the
> earnings outlook for the medical devices company improved dramatically
[quoted text clipped - 4 lines]
> Medicaid Sevices means it will now be reimbursed at a rate of $3,750,
> twice that of the old rate.
Gee Don, I had no idea Laserscope was being reimbursed for anything. It
was my impression that Hospitals would purchase the (fine) device and
reap the rewards?
If you are the Don (St. Agustine) that mentioned to me that Laserscope
might be a good investment, I agree.<bfg